AFP and liver cancer: The results revealed that patients with BMI ≤ 20.425 (the dose limitation of V15 < 34.90%), ECOG = 1–2 (<33.67%), Alpha-fetoprotein (AFP) ≥ 400 ng/ml (<33.20%), Barcelona clinic liver cancer (BCLC) = C (<39.45%),  HBV -positive (<34.90%) and hepatic fibrosis (<34.90%) required a lower dose of V15 (Table S3).